Outcome of Breast Cancer Patients with COVID-19 Infection: A Report from a Tertiary Cancer Center in India

Main Article Content

Indhuja Muthiah Vaikundaraja
Manikandan Dhanushkodi
Venkatraman Radhakrishnan
Jayachandran Peumal Kalaiyarasi
Gangothri Selvarajan
Siva Sree Kesana
Carthikeyan SM
Priya Iyer
Balasubramanian Ananthi
Arvind Krishnamurthy
Sridevi Velusamy
Tenali Gnana Sagar


Breast cancer, COVID-19 infection, Outcome


Background: There is no data on the outcome of COVID-19 infection in patients with breast cancer from India. This study was done to assess the outcome of patients with breast cancer who had COVID-19 infection.

Methods: We analyzed patients with breast cancer who were diagnosed with COVID-19 infection from May to September 2020 in the medical oncology department of a tertiary cancer center in India. Symptomatic patients (fever and influenza-like illness symptoms) or asymptomatic patients planned for systemic therapy were tested for COVID-19 by RT-PCR.

Results: A total of 441 breast cancer patients received 1174 systemic therapies from May to September 2020. Among them, 36 patients who had COVID-19 infection were analyzed in detail. The majority (86%) were asymptomatic at presentation. The most common symptoms were fever followed by cough. Patients were either admitted to the hospital (53%) or kept in home quarantine (47%). Patients who received oxygen, non-invasive assisted ventilation (NIV), and mechanical ventilation (MV) were 8%, 3%, and 3% respectively. The median duration of hospitalization and home quarantine was 11 days and 19 days respectively. The recovery of patients with COVID-19 infection was 94%. The median duration to clearing SARS-COV-2 by RT-PCR was 19 days. The total/all-cause mortality was 6% (n=2). The mortality due to COVID-19 infection was 3% (n=1). Subsequently, 89% were restarted on systemic therapy. The median delay in restarting systemic therapy was 23 days.

Conclusion: Systemic therapy can be safely administered during the ongoing COVID19 pandemic. Further, follow-up of patients is warranted to assess the long-term impact of COVID-19 infection.


1. 356-india-fact-sheets.pdf [Internet]. [cited 2021 Apr 15]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf
2. India Coronavirus: 14,074,564 Cases and 173,152 Deaths - Worldometer [Internet]. [cited 2021 Apr 15]. Available from: https://www.worldometers.info/coronavirus/country/india/
3. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020;10(6):783–91.
4. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology. 2020 Mar 1;21(3):335–7.
5. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol. 2020 Jul 1;6(7):1108–10.
6. Garassino MC, Whisenant JG, Huang L-C, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. The Lancet Oncology. 2020 Jul;21(7):914–22.
7. Vatansev H, Kadiyoran C, Cumhur Cure M, Cure E. COVID-19 infection can cause chemotherapy resistance development in patients with breast cancer and tamoxifen may cause susceptibility to COVID-19 infection. Med Hypotheses. 2020 Oct;143:110091.
8. Vanni G, Materazzo M, Pellicciaro M, Ingallinella S, Rho M, Santori F, et al. Breast Cancer and COVID-19: The Effect of Fear on Patients’ Decision-making Process. In Vivo. 2020 Jun;34(3 Suppl):1651–9.
9. Gathani T, Clayton G, MacInnes E, Horgan K. The COVID-19 pandemic and impact on breast cancer diagnoses: what happened in England in the first half of 2020. British Journal of Cancer. 2021 Feb;124(4):710–2.
10. Gasparri ML, Gentilini OD, Lueftner D, Kuehn T, Kaidar-Person O, Poortmans P. Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST). Breast. 2020 Aug;52:110–5.
11. Brown AH, Shah S, Groves AM, Wan S, Malhotra A. The Challenge of Staging Breast Cancer With PET/CT in the Era of COVID Vaccination. Clin Nucl Med. 2021 Apr 1;
12. Registry Study Describes COVID-19 Mortality and Hospitalization in Patients with Breast Cancer. The Oncologist. 2021;26(S2):S17–8.
13. Vuagnat P, Frelaut M, Ramtohul T, Basse C, Diakite S, Noret A, et al. COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area. Breast Cancer Res [Internet]. 2020 [cited 2021 Apr 15];22. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254663/
14. Zhang B, Xie R, Hubert SM, Yu Y, Zhang Y, Lei X, et al. Characteristics and Outcomes of 35 Breast Cancer Patients Infected With COVID-19. Front Oncol [Internet]. 2020 [cited 2021 Apr 15];10. Available from: https://www.frontiersin.org/articles/10.3389/fonc.2020.570130/full
15. Ovett J, Dhanushkodi M, Radhakrishnan V, Mehra N, Perumal Kalaiyarasi J, Selvarajan G, et al. Coronavirus disease (COVID-19) testing in asymptomatic patients planned for daycare systemic therapy: A tertiary cancer center experience. Indian journal of medical and paediatric oncology. 2020 Nov 12;
16. de Azambuja E, Trapani D, Loibl S, Delaloge S, Senkus E, Criscitiello C, et al. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. ESMO Open. 2020;5:e000793.

Article Statistics :Views : 75 | Downloads : 6 : 1